Latest filings (excl ownership)
10-Q
2024 Q2
Quarterly report
7 Aug 24
8-K
Intra-cellular Therapies Reports Second Quarter 2024
7 Aug 24
S-8
Registration of securities for employees
25 Jun 24
8-K
Departure of Directors or Certain Officers
18 Jun 24
8-K
Other Events
18 Jun 24
10-Q
2024 Q1
Quarterly report
7 May 24
8-K
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Other Events
24 Apr 24
8-K
Entry into a Material Definitive Agreement
18 Apr 24
424B5
Prospectus supplement for primary offering
18 Apr 24
8-K
Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
16 Apr 24
424B5
Prospectus supplement for primary offering
16 Apr 24
S-3ASR
Automatic shelf registration
16 Apr 24
8-K
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
16 Apr 24
8-K
Other Events
1 Apr 24
8-K
Intra-cellular Therapies Announces Executive Appointments and Leadership Changes
19 Mar 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
22 Feb 24
8-K
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
2 Nov 23
10-Q
2023 Q3
Quarterly report
2 Nov 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
3 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
23 Jun 23
10-Q
2023 Q1
Quarterly report
4 May 23
8-K
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
4 May 23
ARS
2022 FY
Annual report to shareholders
28 Apr 23
DEFA14A
Additional proxy soliciting materials
28 Apr 23
DEF 14A
Definitive proxy
28 Apr 23
8-K
Other Events
28 Mar 23
10-K
2022 FY
Annual report
1 Mar 23
8-K
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2022 Financial Results and Provides Corporate Update
1 Mar 23
8-K
Entry into a Material Definitive Agreement
9 Jan 23
8-K
Entry into a Material Definitive Agreement
22 Dec 22
10-Q
2022 Q3
Quarterly report
3 Nov 22
8-K
Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
3 Nov 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
9 Aug 22
Latest ownership filings
4
RORY B RIGGS
2 Oct 24
144
Notice of proposed sale of securities
6 Sep 24
4
Sharon Mates
30 Aug 24
144
Notice of proposed sale of securities
30 Aug 24
144
Notice of proposed sale of securities
29 Aug 24
4
Sharon Mates
28 Aug 24
144
Notice of proposed sale of securities
28 Aug 24
144
Notice of proposed sale of securities
27 Aug 24
144
Notice of proposed sale of securities
26 Aug 24
4
Sharon Mates
23 Aug 24
144
Notice of proposed sale of securities
23 Aug 24
144
Notice of proposed sale of securities
22 Aug 24
144
Notice of proposed sale of securities
21 Aug 24
4
Mark Neumann
20 Aug 24
144
Notice of proposed sale of securities
16 Aug 24
4
Sanjeev Narula
14 Aug 24
3
Sanjeev Narula
14 Aug 24
4
NOSTRAND ROBERT L VAN
2 Jul 24
4
RORY B RIGGS
2 Jul 24
4
NOSTRAND ROBERT L VAN
25 Jun 24
4
Eduardo Rene Salas
25 Jun 24
4
JOEL S MARCUS
25 Jun 24
4
RORY B RIGGS
25 Jun 24
4
NOSTRAND ROBERT L VAN
21 Jun 24
4
Eduardo Rene Salas
18 Jun 24
4
RORY B RIGGS
18 Jun 24
4
JOEL S MARCUS
18 Jun 24
4
NOSTRAND ROBERT L VAN
18 Jun 24
144
Notice of proposed sale of securities
18 Jun 24
4
Sharon Mates
25 Apr 24
4
NOSTRAND ROBERT L VAN
2 Apr 24
4
RORY B RIGGS
2 Apr 24
4
RORY B RIGGS
22 Mar 24
4
Sharon Mates
11 Mar 24
4
Lawrence J. Hineline
11 Mar 24
4
Michael Halstead
11 Mar 24
4
Mark Neumann
11 Mar 24
4
Suresh K. Durgam
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24